Business Context and Reporting Period
Company: LifeMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2025
Event: LifeMD, Inc. entered into and consummated a Stock Purchase Agreement to sell 80% of the outstanding units of WorkSimpli Software LLC (the "Company") to Lion Buyer, LLC (the "Purchaser").
Key Financial Metrics and Transaction Details
This filing details a specific asset disposition rather than general operating results. Key financial terms of the transaction include:
- Enterprise Value: Approximately $65.0 million.
- Total Aggregate Purchase Consideration: Up to $52.0 million payable to the Sellers.
- LifeMD's Pro Rata Share: LifeMD held 91.6% of the units sold.
- Cash at Closing (Base Purchase Price): $24.0 million total ($22.0 million to LifeMD), subject to working capital and debt adjustments.
- Performance-Based Consideration: Up to $26.0 million total (up to $23.8 million to LifeMD) contingent on Adjusted EBITDA targets from January 1, 2026, through the third anniversary.
- Activation Amount: $2.0 million total (up to $1.8 million to LifeMD) contingent on subscription targets within 12 months of closing.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or operating metrics for the prior period. The material change reported is the divestiture of a significant asset (80% of WorkSimpli Software LLC), which alters the company's asset base and future revenue streams associated with that entity.
Guidance, Outlook, and Risks
Management Commentary: The transaction was executed via electronic exchange on November 4, 2025. A portion of the base purchase price was held back as an adjustment holdback to cover post-closing adjustments.
Contingencies and Risks:
- Performance Targets: Approximately 53.8% of the total consideration ($28.0 million) is contingent upon future performance metrics (Adjusted EBITDA and subscription targets).
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from projections due to risks and uncertainties.
- Legal Disclaimer: Representations and warranties in the Purchase Agreement are not intended to be relied upon by investors as characterizations of actual facts.
Important Facts for Investor Verification
- Verify the final post-closing adjustments to the $22.0 million base cash payment to LifeMD.
- Monitor WorkSimpli Software LLC's Adjusted EBITDA performance from January 1, 2026, to determine the realization of the up to $23.8 million performance earn-out.
- Track subscription targets for WorkSimpli to determine the realization of the up to $1.8 million activation amount.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for specific definitions of "Adjusted EBITDA" and "subscription targets."